(E)-cinnamyl 3-(3,4-dihydroxyphenyl)-2-methylacrylate | 1579956-04-9

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: (E)-cinnamyl 3-(3,4-dihydroxyphenyl)-2-methylacrylate
• 英文别名: [(E)-3-phenylprop-2-enyl] (E)-3-(3,4-dihydroxyphenyl)-2-methylprop-2-enoate
• CAS: 1579956-04-9
• 化学式: C₁₉H₁₈O₄
• 分子量: 310.35
• InChiKey: RELYZENLCUKPCR-LNNJPWRLSA-N

物化性质

• 熔点：
  139 °C
• 沸点：
  533.8±50.0 °C(Predicted)
• 密度：
  1.246±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  23
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  66.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  3,4-双(甲氧基甲氧基)苯甲醛 在 盐酸 、 4-二甲氨基吡啶 、 水 、 sodium hydride 、 N,N'-二环己基碳二亚胺 、 lithium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 mineral oil 为溶剂， 反应 25.0h， 生成 (E)-cinnamyl 3-(3,4-dihydroxyphenyl)-2-methylacrylate
  参考文献：
  名称：

  Synthesis and structure–activity relationship study of substituted caffeate esters as antinociceptive agents modulating the TREK-1 channel

  摘要：

  The TWIK-related K+ channel, TREK-1, has recently emerged as an attractive therapeutic target for the development of a novel class of analgesic drugs. It has been reported that TREK-1 -/- mice were more sensitive than wild-type mice to painful stimuli, suggesting that activation of TREK-1 could result in pain inhibition. Here we report the synthesis of a series of substituted caffeate esters (12a-u) based on the hit compound CDC 2 (cinnamyl 3,4-dihydroxyl-alpha-cyanocinnamate). These analogs were evaluated for their ability to modulate TREK-1 channel by electrophysiology and for their in vivo antinociceptive activity (acetic acid induced-writhing assay) leading to the identification a series of novel molecules able to activate TREK-1 and displaying potent analgesic activity in vivo. (C) 2014 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2014.01.049

文献信息

• ACTIVATOR OF TREK (TWIK RELATED K+ CHANNELS) CHANNELS
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：US20210347773A1

  公开（公告）日：2021-11-11

  Disclosed is a compound of formula (I): wherein all symbols are defined in the description. Also disclosed are pharmaceutical compositions comprising the compounds, methods of making the compounds, kits comprising the compounds, and methods of using the compounds, compositions and kits for treatment of disorders associated with TREK-1, TREK-2 or both TREK-1 and TREK-2 dysfunction in a mammal.